Albendazole-ivermectin reshaped the gut microbiome in a country-specific way

Mass deworming rarely stops at the worm. In the ALIVE trial, stool metagenomics from children in Ethiopia and Mozambique showed that albendazole-ivermectin did more than target soil-transmitted helminths; it also shifted the intestinal bacterial ecosystem, and the signal was strongest in Ethiopia after three consecutive daily doses. Baseline microbiome structure separated by country far more than by infection status, a reminder that geography, diet, environment, and prior microbial exposure can dominate the baseline signal in pediatric gut ecology. Infection itself did not neatly sort the microbiome into distinct groups, and neither baseline composition nor the pre-treatment resistome predicted albendazole efficacy or adverse events.

The finding matters because deworming programs are usually judged on antiparasitic effect alone. Here, the treatment arms carried an ecological footprint inside the gut, and the footprint was not uniform across settings.

Enterobacteriaceae depletion tracked with E. coli loss and resistance-gene reductions

The clearest microbial change followed the co-formulation arm, especially the regimen given on three consecutive days. In Ethiopian children, Enterobacteriaceae declined, with Escherichia coli driving much of the drop. The same pattern extended beyond taxonomy: E. coli-associated resistance genes and metabolic pathways fell in parallel, linking species-level depletion to both resistome and functional remodeling. Genome-resolved analysis strengthened the inference by showing that the signal did not come from a single odd genome or a narrow subpopulation. It appeared across multiple E. coli strain-level populations, pointing to one ecological event rather than a statistical artifact scattered across unrelated bins.

This is the kind of pattern that is hard to dismiss as noise. When taxonomic loss, resistance-gene depletion, and pathway contraction move together, the most plausible explanation is a direct or indirect antibiotic-like pressure on a dominant gut commensal or pathobiont reservoir, even when the intervention is not designed as an antibacterial drug.

Genome-resolved metagenomics gave the signal unusual resolution

The analysis assembled more than 22,000 high-quality metagenome-assembled genomes and mapped them to 1,372 representative MAGs. That depth matters because strain-level behavior is often where population biology becomes clinically meaningful. Two children may both be colonized with E. coli, yet carry distinct strain mixtures with different accessory genes, resistance elements, and metabolic capacities. By resolving the signal across multiple genomes instead of stopping at genus-level abundance, the study linked a treatment effect to the underlying bacterial population structure rather than to a broad, imprecise taxonomic label.

The result also expands the microbial reference space for African pediatric cohorts. Large-scale genome-resolved datasets from these settings remain limited, and every additional curated genome improves future work on colonization, resistance evolution, and regional microbiome baselines.

Country context shaped baseline ecology more than helminth status

The baseline stool profiles were not driven mainly by whether children carried helminths. Instead, country of enrollment explained more of the initial microbiome composition than infection status. That pattern is consistent with what gut microbiology has long suggested in low- and middle-income settings: environmental exposure, sanitation, diet, and local microbial transmission networks can overpower a single disease label. In practical terms, a deworming intervention entering two countries is not entering the same microbial terrain twice. The same drug exposure may therefore produce different ecological consequences depending on the host population and its bacterial starting point.

No comparable baseline association linked microbiome composition to albendazole efficacy or to adverse events. The absence of a predictive signal at baseline narrows what the pre-treatment microbiome can tell clinicians right now. It does not rule out microbiome influence on treatment in other contexts, but it does mean the current dataset did not identify a microbial signature that forecasted antiparasitic response or tolerability.

Why an anthelmintic combo may have bacterial effects

Albendazole is the established workhorse of mass deworming, while ivermectin adds a broader antiparasitic spectrum. Neither drug is marketed as a microbiome-directed therapy, yet pharmacology does not stop at the intended target. If the co-formulation changes bile exposure, gut transit, intestinal niche occupancy, or helminth-mediated microbial buffering, the bacterial community may shift as a downstream consequence. Another possibility is that the drug combination alters the ecological space previously occupied by helminth-associated or helminth-protected bacteria, allowing some populations to contract quickly. The observed depletion of E. coli-associated pathways fits an ecosystem under abrupt selective pressure rather than a slow, diffuse drift.

The strain-level depletion also raises a sharper question for mass drug administration: repeated or intensified dosing could have unmeasured effects on commensal reservoirs and resistance gene carriage, especially in populations where Enterobacteriaceae are already common intestinal residents.

Deworming programs may need to account for off-target microbial effects

Public health deworming campaigns are built to reduce worm burden at scale, often with limited time for individualized monitoring. These results add a bacterial dimension to that strategy. In children treated with the albendazole-ivermectin co-formulation, the microbiome response was not a broad collapse of gut diversity reported in this dataset; it was a selective, taxonomically focused depletion with functional echoes in the resistome. That kind of response could matter if repeated population-wide treatment nudges gut communities toward altered colonization resistance or shifts the reservoir of resistance genes carried by common Enterobacteriaceae.

The preprint remains limited by its status and by the fact that the strongest effect emerged in one country and under a specific dosing pattern. The study does not establish clinical harm, and it does not show that microbiome changes translate into symptoms or long-term outcomes. What it does show is more precise and more unsettling for program designers: a deworming regimen intended for parasites also touched a core bacterial lineage, and it did so in a population-dependent way.

Trial identifier and data trail

The work comes from the ALIVE clinical trial, registered as NCT05124691. Sequencing data were deposited in the European Nucleotide Archive under BioProject PRJEB79832, and the assembled genomes were deposited in Zenodo under DOI:10.5281/zenodo.24111237. Those resources should make it possible to test whether the E. coli signal persists across analytic methods, whether it reappears in other dosing schedules, and whether similar off-target microbiome effects show up in other deworming settings.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by medRxiv (Clinical Preprints).
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA